Glypican-3 expression in clear cell adenocarcinoma of the ovary.
about
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinomaCurrent concepts in the immunohistochemical evaluation of liver tumorsSALL4 expression in germ cell and non-germ cell tumors: a systematic immunohistochemical study of 3215 casesPerioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growthSignificant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.Glypican-3: a new target for cancer immunotherapy.Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.Expression of Glypican 3 in low and high grade urothelial carcinomas.Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.Novel biomarker candidates for the diagnosis of ovarian clear cell carcinomaPathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review).Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.Expression of Markers of Hepatocellular Differentiation in Pancreatic Acinar Cell Neoplasms: A Potential Diagnostic Pitfall.Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.Elevated GPC3 level promotes cell proliferation in liver cancer.
P2860
Q26772321-DEDFF260-8B57-4331-AADB-DAFD57E0DB21Q26864205-6456CEE1-7F49-4627-8732-480C4492825FQ28307647-1A40C174-E20D-4898-BA44-629F7C61C147Q33914169-33F05BA2-51E1-4750-A508-CFA520B96541Q34000565-0A8FBB45-F9F0-4D13-9B15-B6920DE8D7AAQ34290698-597888D0-94AE-4266-996D-519BF5D19314Q34372167-29A510EE-5A92-4791-8AAC-7460259A72A2Q34543102-882B5BB4-07D8-41BD-A85C-17BB8CA9F63DQ35545814-310E7755-DA85-4579-8687-0892F40FF4E7Q35552355-6E17DC24-E1CE-46A1-974E-3177DCCDEC9BQ35768137-EE0A9C7F-5F32-460C-B180-5C51FBF6902FQ35871283-02B86265-BB5C-4AEE-AA57-A45D8E3C2281Q36469640-33165F0C-3761-4B18-85BB-DFAA57307514Q37031710-63603F1A-F297-4705-A501-C7C3F522D58FQ37269461-8CDCC78C-4F37-4672-9AEF-183EE9650756Q37475741-EADE145A-27A9-4874-A2A4-CDFC49CF55B9Q37477273-EAD0FACB-0C62-45E7-976A-CDE15C40438EQ37645001-8B183369-4CF7-4588-A165-BA2D763D4B3BQ47115713-EE3DC675-98DA-4A14-8DDC-F10F410D6985Q47118215-6D2A2C27-BE80-4BD0-9DB6-E21CF245D20AQ47696309-818BA33E-FB32-4E5F-9016-A0AC30A43D69Q55405975-FC7BDA22-638C-4926-A084-4D1980AA41EB
P2860
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
@en
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
@nl
type
label
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
@en
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
@nl
prefLabel
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
@en
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
@nl
P2093
P2860
P1433
P1476
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
@en
P2093
Daichi Maeda
Hiroyuki Aburatani
Masashi Fukayama
Satoshi Ota
Shunsuke Nakagawa
Tatsuhiko Kodama
Tetsu Yano
Yuji Taketani
Yutaka Takazawa
P2860
P2888
P304
P356
10.1038/MODPATHOL.2009.40
P577
2009-03-27T00:00:00Z